

# David A Cameron

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3696909/david-a-cameron-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

218  
papers

26,779  
citations

68  
h-index

163  
g-index

231  
ext. papers

31,170  
ext. citations

10.3  
avg, IF

6.22  
L-index

#	Paper	IF	Citations
218	Anti-Müllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review.. <i>Human Reproduction Update</i> , <b>2022</b> ,	15.8	2
217	Treatment Exposure and Discontinuation in the PALbociclib CoLLaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03).. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 1002101918	2.2	2
216	Collateral-resistance to estrogen and HER-activated growth is associated with modified AKT, ER $\beta$ and cell-cycle signaling in a breast cancer model.. <i>Exploration of Targeted Anti-tumor Therapy</i> , <b>2022</b> , 3, 97-116	2.5	
215	Abstract PD10-05: Activity of atezolizumab (atezo) plus paclitaxel (pac) in metastatic triple-negative breast cancer (mTNBC) according to Burstein molecular subtype: Analysis of the IMpassion131 trial. <i>Cancer Research</i> , <b>2022</b> , 82, PD10-05-PD10-05	10.1	0
214	Abstract PD9-08: Prognostic value of EndoPredict test in patients screened for UNIRAD, a UCBG randomized, double blind, phase III international trial evaluating the addition of everolimus (EVE) to adjuvant hormone therapy (HT) in women with high risk HR+, HER2- early breast cancer (eBC). <i>Cancer Research</i> , <b>2022</b> , 82, PD9-08-PD9-08	10.1	
213	Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.. <i>New England Journal of Medicine</i> , <b>2022</b> , 386, 942-950	59.2	18
212	Code of practice needed for samples donated by trial participants.. <i>Lancet Oncology, The</i> , <b>2022</b> , 23, e89-e907	21.7	2
211	Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial.. <i>European Journal of Cancer</i> , <b>2022</b> , 166, 219-228	7.5	0
210	Central nervous system disease in phase III studies for advanced HER2 positive breast cancer: A review.. <i>Breast</i> , <b>2022</b> , 63, 85-100	3.6	1
209	Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.. <i>Lancet Oncology, The</i> , <b>2021</b> ,	21.7	16
208	Multi-omic machine learning predictor of breast cancer therapy response. <i>Nature</i> , <b>2021</b> ,	50.4	15
207	Strategies for improving access to clinical trials by teenagers and young adults with cancer: A qualitative study of health professionals' views. <i>European Journal of Cancer Care</i> , <b>2021</b> , 30, e13408	2.4	
206	Cancer survivorship: Reproductive health outcomes should be included in standard toxicity assessments. <i>European Journal of Cancer</i> , <b>2021</b> , 144, 310-316	7.5	14
205	Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 2720-2731	2.2	3
204	Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 1139-1150	21.7	24
203	Patterns of genomic change in residual disease after neoadjuvant chemotherapy for estrogen receptor-positive and HER2-negative breast cancer. <i>British Journal of Cancer</i> , <b>2021</b> , 125, 1356-1364	8.7	0
202	Expert Discussion: Highlights from the San Antonio Breast Cancer Symposium, San Antonio, December 8-11, 2020. <i>Breast Care</i> , <b>2021</b> , 16, 89-93	2.4	1

201	Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 2610-2619	2.2	134
200	Distinct temporal trends in breast cancer incidence from 1997 to 2016 by molecular subtypes: a population-based study of Scottish cancer registry data. <i>British Journal of Cancer</i> , <b>2020</b> , 123, 852-859	8.7	11
199	The requirements of a specialist breast centre. <i>Breast</i> , <b>2020</b> , 51, 65-84	3.6	47
198	Protective strategies to prevent trastuzumab-induced cardiotoxicity - AuthorsReply. <i>Lancet, The</i> , <b>2020</b> , 395, 492-493	4.0	
197	Six versus 12 months Adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT. <i>Health Technology Assessment</i> , <b>2020</b> , 24, 1-190	4.4	2
196	The challenges of making informed decisions about treatment and trial participation following a cancer diagnosis: a qualitative study involving adolescents and young adults with cancer and their caregivers. <i>BMC Health Services Research</i> , <b>2020</b> , 20, 25	2.9	7
195	Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , <b>2020</b> , 382, 597-609	59.2	396
194	Breast cancer gene expression datasets do not reflect the disease at the population level. <i>Npj Breast Cancer</i> , <b>2020</b> , 6, 39	7.8	2
193	Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, 1296-1308	21.7	72
192	Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2019</b> , 4, 854-862	18.8	25
191	On-treatment biomarkers can improve prediction of response to neoadjuvant chemotherapy in breast cancer. <i>Breast Cancer Research</i> , <b>2019</b> , 21, 73	8.3	19
190	6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. <i>Lancet, The</i> , <b>2019</b> , 393, 2599-2612	4.0	131
189	Combining clustering and classification ensembles: A novel pipeline to identify breast cancer profiles. <i>Artificial Intelligence in Medicine</i> , <b>2019</b> , 97, 27-37	7.4	18
188	Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes. <i>British Journal of Cancer</i> , <b>2019</b> , 120, 913-921	8.7	7
187	Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial. <i>Anticancer Research</i> , <b>2019</b> , 39, 797-802	2.3	
186	Do patients whose tumor achieved a pathological response relapse at specific sites? A substudy of the EORTC 10994/BIG-1-00 trial. <i>Breast Cancer Research and Treatment</i> , <b>2018</b> , 169, 497-505	4.4	1
185	Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial. <i>Journal of the National Cancer Institute</i> , <b>2018</b> , 110, 871-879	9.7	23
184	Adjuvant trastuzumab duration trials in HER2 positive breast cancer - what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results. <i>BMC Cancer</i> , <b>2018</b> , 18, 391	4.8	6

183	Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy. <i>Journal of the National Cancer Institute</i> , <b>2018</b> , 110,	9.7	49
182	Overall survival in MERiDiAN, a double-blind placebo-controlled randomised phase III trial evaluating first-line bevacizumab plus paclitaxel for HER2-negative metastatic breast cancer. <i>European Journal of Cancer</i> , <b>2018</b> , 90, 153-155	7.5	13
181	Reproductive hormone analyses and effects of adjuvant zoledronic acid in early breast cancer - An AZURE (BIG 01/04) sub-study. <i>Journal of Bone Oncology</i> , <b>2017</b> , 9, 48-54	4.5	4
180	11 years of follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. <i>Lancet, The</i> , <b>2017</b> , 389, 1195-1205	40	486
179	High hospital research participation and improved colorectal cancer survival outcomes: a population-based study. <i>Gut</i> , <b>2017</b> , 66, 89-96	19.2	64
178	Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study. <i>Breast Cancer</i> , <b>2017</b> , 14, 507-515	4.4	3
177	Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 755-769	21.7	13
176	Factors predictive of locoregional recurrence following neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancer: An analysis of the EORTC 10994/BIG 1-00 study. <i>European Journal of Cancer</i> , <b>2017</b> , 79, 226-234	7.5	23
175	Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 929-945	21.7	38
174	Correlation between severe infection and breast cancer metastases in the EORTC 10994/BIG 1-00 trial: Investigating innate immunity as a tumour suppressor in breast cancer. <i>European Journal of Cancer</i> , <b>2017</b> , 72, 95-102	7.5	3
173	Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 1543-1552	21.7	32
172	Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA Prelim Trial. <i>Value in Health</i> , <b>2017</b> , 20, 1311-1318	3.3	21
171	Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation. <i>European Journal of Cancer</i> , <b>2017</b> , 70, 146-155	7.5	88
170	Concerns about cardiotoxicity in the HERA trial - Authors Reply. <i>Lancet, The</i> , <b>2017</b> , 390, 2767-2768	40	
169	Trastuzumab-associated cardiac events in the Persephone trial. <i>British Journal of Cancer</i> , <b>2016</b> , 115, 1462-1470	20	
168	ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. <i>Contemporary Clinical Trials</i> , <b>2016</b> , 51, 56-64	2.3	99
167	Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 936-44	2.2	14
166	Characterizing and quantifying the effects of breast cancer therapy using mathematical modeling. <i>Breast Cancer Research and Treatment</i> , <b>2016</b> , 155, 303-11	4.4	2

165	Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience. <i>Breast Cancer Research and Treatment</i> , <b>2016</b> , 155, 127-32	4.4	6
164	OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer. <i>Health Technology Assessment</i> , <b>2016</b> , 20, xxiii-xxix, 1-201	4.4	42
163	Treatment of Screen-Detected Breast Cancer: Can We Avoid or Minimize Overtreatment? <b>2016</b> , 375-401		1
162	Adjuvant Systemic Treatment for Breast Cancer: An Overview <b>2016</b> , 311-321		
161	Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others. <i>Journal of the National Cancer Institute</i> , <b>2016</b> , 108,	9.7	114
160	England 30-day chemotherapy mortality: a measure of quality of care?. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, 1172-3	21.7	2
159	Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 1738-1748	59.2	975
158	Nottingham Prognostic Index Plus: Validation of a clinical decision making tool in breast cancer in an independent series. <i>Journal of Pathology: Clinical Research</i> , <b>2016</b> , 2, 32-40	5.3	24
157	Species differences in tumour responses to cancer chemotherapy. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , <b>2015</b> , 370,	5.8	17
156	Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTEMIS): an open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 656-66	21.7	93
155	Removing the primary tumour in metastatic breast cancer. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 1284-5	21.7	4
154	Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1680-7	2.2	47
153	Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 266-73	21.7	485
152	FKBPL: a marker of good prognosis in breast cancer. <i>Oncotarget</i> , <b>2015</b> , 6, 12209-23	3.3	9
151	Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. <i>Lancet, The</i> , <b>2014</b> , 384, 164-72	40	2177
150	Breast cancer chemoprevention: little progress in practice?. <i>Lancet, The</i> , <b>2014</b> , 383, 1018-20	40	6
149	Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, 997-1006	21.7	216
148	Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01). <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2159-65	2.2	164

147	A highly-sensitive anti-Müllerian hormone assay improves analysis of ovarian function following chemotherapy for early breast cancer. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 2367-74	7.5	31
146	Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?. <i>Breast Cancer Research</i> , <b>2013</b> , 15, R31	8.3	1
145	2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. <i>Lancet, The</i> , <b>2013</b> , 382, 1021-8	40	377
144	Pertuzumab for the treatment of metastatic breast cancer. <i>Expert Review of Anticancer Therapy</i> , <b>2013</b> , 13, 907-18	3.5	6
143	Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2013</b> , 14, 933-42	21.7	318
142	Authors Reply. <i>Journal of Pathology</i> , <b>2013</b> , 229, e2-3	9.4	
141	Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer. <i>European Journal of Cancer</i> , <b>2013</b> , 49, 3404-11	7.5	90
140	CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). <i>Lancet Oncology, The</i> , <b>2013</b> , 14, 244-8	21.7	126
139	Phosphorylation of AKT pathway proteins is not predictive of benefit of taxane therapy in early breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2013</b> , 138, 773-81	4.4	9
138	Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. <i>Annals of Oncology</i> , <b>2013</b> , 24, 355-361	10.3	64
137	Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 1954-60	2.2	28
136	Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04). <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2685-91	2.2	35
135	1st International consensus guidelines for advanced breast cancer (ABC 1). <i>Breast</i> , <b>2012</b> , 21, 242-52	3.6	258
134	Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. <i>Annals of Surgical Oncology</i> , <b>2012</b> , 19, 1508-16	3.1	329
133	The p160 ER co-regulators predict outcome in ER negative breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2012</b> , 131, 463-72	4.4	15
132	Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab. <i>European Journal of Health Economics</i> , <b>2012</b> , 13, 589-603	3.6	17
131	Impact of screening and risk factors for local recurrence and survival after conservative surgery and radiotherapy for early breast cancer: results from a large series with long-term follow-up. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2012</b> , 83, 829-38	4	16
130	Advancing cancer drug discovery towards more agile development of targeted combination therapies. <i>Future Medicinal Chemistry</i> , <b>2012</b> , 4, 87-105	4.1	17



129	The EORTC Breast Cancer Group: major achievements of 50 years of research and future directions. <i>European Journal of Cancer, Supplement</i> , <b>2012</b> , 10, 27-33	1.6	1
128	Trial design on prophylaxis and treatment of brain metastases: lessons learned from the EORTC Brain Metastases Strategic Meeting 2012. <i>European Journal of Cancer</i> , <b>2012</b> , 48, 3439-47	7.5	33
127	Proximity ligation assays for isoform-specific Akt activation in breast cancer identify activated Akt1 as a driver of progression. <i>Journal of Pathology</i> , <b>2012</b> , 227, 481-9	9.4	26
126	Chromosome instability and benefit from adjuvant anthracyclines in breast cancer. <i>British Journal of Cancer</i> , <b>2012</b> , 107, 71-4	8.7	25
125	Expression of activated type I receptor tyrosine kinases in early breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2012</b> , 134, 701-8	4.4	3
124	In situ detection of HER2:HER2 and HER2:HER3 protein-protein interactions demonstrates prognostic significance in early breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2012</b> , 132, 463-70	4.4	58
123	The Royal College of Physicians Simms Lecture, 6 December 2011: clinical research networks and the benefits of intensive healthcare systems. <i>Clinical Medicine</i> , <b>2012</b> , 12, 446-52	1.9	5
122	Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials. <i>British Journal of Cancer</i> , <b>2012</b> , 107, 1257-67	8.7	13
121	Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer. <i>Journal of the National Cancer Institute</i> , <b>2012</b> , 104, 56-66	9.7	64
120	Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering duration of benefit, long-term toxicity and pattern of recurrence. <i>Pharmacoeconomics</i> , <b>2011</b> , 29, 415-32	4.4	42
119	Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. <i>Lancet Oncology, The</i> , <b>2011</b> , 12, 236-44	21.7	500
118	TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. <i>Lancet Oncology, The</i> , <b>2011</b> , 12, 527-39	21.7	101
117	HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. <i>Lancet Oncology, The</i> , <b>2011</b> , 12, 1134-42	21.7	141
116	Developing an international network for breast cancer research: the BIG experience. <i>Clinical Investigation</i> , <b>2011</b> , 1, 623-628		2
115	Strengthening clinical cancer research in the United Kingdom. <i>British Journal of Cancer</i> , <b>2011</b> , 104, 1529-34	8.4	31
114	Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2011</b> , 127, 429-38	4.4	90
113	Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. <i>Oncologist</i> , <b>2011</b> , 16, 1092-100	5.7	181
112	Breast-cancer adjuvant therapy with zoledronic acid. <i>New England Journal of Medicine</i> , <b>2011</b> , 365, 1396-405	45.2	378

111	Adjuvant chemotherapy in older women (ACTION) study - what did we learn from the pilot phase?. <i>British Journal of Cancer</i> , <b>2011</b> , 105, 1260-6	8.7	41
110	Pretreatment serum anti-Müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2011</b> , 96, 1336-43	5.6	171
109	Targeting anthracyclines in early breast cancer: new candidate predictive biomarkers emerge. <i>Oncogene</i> , <b>2010</b> , 29, 5231-40	9.2	27
108	Opportunities for PET to deliver clinical benefit in cancer: breast cancer as a paradigm. <i>Cancer Imaging</i> , <b>2010</b> , 10, 144-52	5.6	8
107	Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 2688-95	12.9	115
106	Intensive loading dose of trastuzumab achieves higher-than-steady-state serum concentrations and is well tolerated. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 960-6	2.2	31
105	Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 1131-7	2.2	135
104	Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. <i>Oncologist</i> , <b>2010</b> , 15, 924-34	5.7	227
103	Health economics in drug development: efficient research to inform healthcare funding decisions. <i>European Journal of Cancer</i> , <b>2010</b> , 46, 2674-80	7.5	13
102	Breast cancer in pregnancy: recommendations of an international consensus meeting. <i>European Journal of Cancer</i> , <b>2010</b> , 46, 3158-68	7.5	186
101	Intraoperative radiotherapy for early breast cancer. <i>Lancet, The</i> , <b>2010</b> , 376, 1142; author reply 1143-4	4.0	5
100	Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). <i>Lancet Oncology, The</i> , <b>2010</b> , 11, 266-74	21.7	109
99	Triple-negative breast cancer: disease entity or title of convenience?. <i>Nature Reviews Clinical Oncology</i> , <b>2010</b> , 7, 683-92	19.4	588
98	Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy. <i>Breast Cancer Research</i> , <b>2010</b> , 12, R47	8.3	92
97	Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer. <i>Breast Cancer Research</i> , <b>2010</b> , 12, R39	8.3	34
96	Bone mineral density loss during adjuvant chemotherapy in pre-menopausal women with early breast cancer: is it dependent on oestrogen deficiency?. <i>Breast Cancer Research and Treatment</i> , <b>2010</b> , 123, 805-14	4.4	53
95	Five-year outcome for women randomised in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: an Anglo-Celtic Cooperative Oncology Group study. <i>Breast Cancer Research and Treatment</i> , <b>2010</b> , 122, 787-94	4.4	10
94	Lapatinib in the management of breast cancer. <i>Therapy: Open Access in Clinical Medicine</i> , <b>2009</b> , 6, 553-568		



93	Increase in response rate by prolonged treatment with neoadjuvant letrozole. <i>Breast Cancer Research and Treatment</i> , <b>2009</b> , 113, 145-51	4.4	80
92	Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment. <i>Breast Cancer Research and Treatment</i> , <b>2009</b> , 117, 577-89	4.4	49
91	Histological grading of invasive breast carcinoma--a simplification of existing methods in a large conservation series with long-term follow-up. <i>Histopathology</i> , <b>2009</b> , 55, 724-31	7.3	24
90	A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. <i>Nature Medicine</i> , <b>2009</b> , 15, 68-74	50.5	477
89	Ras/Raf-1/MAPK pathway mediates response to tamoxifen but not chemotherapy in breast cancer patients. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 1487-95	12.9	64
88	Current perspective - trastuzumab. <i>European Journal of Cancer</i> , <b>2009</b> , 45, 12-8	7.5	46
87	Predictive signatures for chemotherapy sensitivity in breast cancer: are they ready for use in the clinic?. <i>European Journal of Cancer</i> , <b>2009</b> , 45, 1733-43	7.5	28
86	A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases. <i>Clinical Breast Cancer</i> , <b>2009</b> , 9, 39-44	3	35
85	Foundation clinical trials. <i>Breast Cancer Research</i> , <b>2009</b> , 11 Suppl 3, S23	8.3	1
84	An economic evaluation of docetaxel and paclitaxel regimens in metastatic breast cancer in the UK. <i>Pharmacoeconomics</i> , <b>2009</b> , 27, 847-59	4.4	16
83	Lapatinib for inflammatory breast cancer. <i>Lancet Oncology, The</i> , <b>2009</b> , 10, 538-9	21.7	5
82	Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. <i>Lancet, The</i> , <b>2009</b> , 373, 1681-92	40	144
81	Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer. <i>British Journal of Cancer</i> , <b>2008</b> , 99, 711-5	8.7	30
80	Economic evaluation of fulvestrant as an extra step in the treatment sequence for ER-positive advanced breast cancer. <i>British Journal of Cancer</i> , <b>2008</b> , 99, 1984-90	8.7	16
79	Cell killing and resistance in pre-operative breast cancer chemotherapy. <i>BMC Cancer</i> , <b>2008</b> , 8, 201	4.8	10
78	Promises borne out in clinical studies. <i>European Journal of Cancer, Supplement</i> , <b>2008</b> , 6, 15-24	1.6	
77	Bevacizumab: the first anti-angiogenic agent approved for the treatment of metastatic breast cancer. <i>European Journal of Cancer, Supplement</i> , <b>2008</b> , 6, 1-6	1.6	4
76	Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer. <i>Nature Clinical Practice Oncology</i> , <b>2008</b> , 5, 512-20		68

75	The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients. <i>European Journal of Cancer</i> , <b>2008</b> , 44, 353-65	7.5	16
74	Extended follow-up of breast cancer patients in clinic wastes time for both patients and doctors: the case against. <i>Breast Cancer Research</i> , <b>2008</b> , 10 Suppl 4, S8	8.3	3
73	HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 7861-70	12.9	137
72	Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. <i>Annals of Oncology</i> , <b>2008</b> , 19, 877-82	10.3	52
71	Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 4883-90	2.2	261
70	Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 1671-6	2.2	137
69	Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 1948-55	2.2	156
68	Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 5027-35	2.2	80
67	Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. <i>Annals of Oncology</i> , <b>2008</b> , 19, 1090-6	10.3	146
66	Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 925-33	2.2	31
65	A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. <i>Breast Cancer Research and Treatment</i> , <b>2008</b> , 112, 533-43	4.4	631
64	Histopathology of breast carcinoma following neoadjuvant systemic therapy: a common association between letrozole therapy and central scarring. <i>Histopathology</i> , <b>2007</b> , 51, 219-26	7.3	28
63	Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer. <i>Gynecologic Oncology</i> , <b>2007</b> , 106, 461-8	4.9	60
62	Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 2006-11	2.2	112
61	Health care costs for the treatment of breast cancer recurrent events: estimates from a UK-based patient-level analysis. <i>British Journal of Cancer</i> , <b>2007</b> , 97, 479-85	8.7	27
60	Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling. <i>Molecular Cancer Therapeutics</i> , <b>2007</b> , 6, 93-100	6.1	51
59	Progressive loss of estrogen receptor alpha cofactor recruitment in endocrine resistance. <i>Molecular Endocrinology</i> , <b>2007</b> , 21, 2615-26		19
58	Assessment of the effect of chemotherapy on ovarian function in women with breast cancer. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 1630-1; author reply 1632	2.2	25

57	Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 4423-30	2.2	59
56	Insulin-like growth factor binding proteins IGFBP3, IGFBP4, and IGFBP5 predict endocrine responsiveness in patients with ovarian cancer. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 1438-44	12.9	50
55	2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. <i>Lancet, The</i> , <b>2007</b> , 369, 29-36	40	1177
54	Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. <i>Lancet Oncology, The</i> , <b>2007</b> , 8, 1071-1078	21.7	170
53	Lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer. <i>Clinical Advances in Hematology and Oncology</i> , <b>2007</b> , 5, 456-8	0.6	9
52	The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. <i>Human Reproduction</i> , <b>2006</b> , 21, 2583-92	5.7	278
51	Ibandronate: its role in metastatic breast cancer. <i>Oncologist</i> , <b>2006</b> , 11 Suppl 1, 27-33	5.7	22
50	Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models. <i>Endocrine-Related Cancer</i> , <b>2006</b> , 13, 1121-33	5.7	42
49	Raf-1 is the predominant Raf isoform that mediates growth factor-stimulated growth in ovarian cancer cells. <i>Carcinogenesis</i> , <b>2006</b> , 27, 729-39	4.6	34
48	Lapatinib plus capecitabine for HER2-positive advanced breast cancer. <i>New England Journal of Medicine</i> , <b>2006</b> , 355, 2733-43	59.2	2641
47	Quality of life and sexual function after high-dose or conventional chemotherapy for high-risk breast cancer. <i>British Journal of Cancer</i> , <b>2006</b> , 95, 1626-31	8.7	36
46	Safety of oral ibandronate in the treatment of bone metastases from breast cancer : long-term follow-up experience. <i>Clinical Drug Investigation</i> , <b>2006</b> , 26, 43-8	3.2	20
45	Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. <i>Breast Cancer Research and Treatment</i> , <b>2006</b> , 99, 295-300	4.4	77
44	Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 2988-95	2.2	147
43	Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. <i>Journal of the National Cancer Institute</i> , <b>2005</b> , 97, 1262-71	9.7	918
42	Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. <i>New England Journal of Medicine</i> , <b>2005</b> , 353, 1659-72	59.2	3921
41	Identification of molecular apocrine breast tumours by microarray analysis. <i>Oncogene</i> , <b>2005</b> , 24, 4660-71	9.2	594
40	Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 8322-30	2.2	45

39	Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. <i>British Journal of Cancer</i> , <b>2005</b> , 92, 1869-76	8.7	134
38	The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, a randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal women. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 2117-21	10.3	71
37	Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial. <i>Journal of the National Cancer Institute</i> , <b>2004</b> , 96, 1076-83	9.7	56
36	A prognostic index for operable, node-negative breast cancer. <i>British Journal of Cancer</i> , <b>2004</b> , 90, 1933-48	8.7	16
35	Maximizing clinical benefit with trastuzumab. <i>Seminars in Oncology</i> , <b>2004</b> , 31, 35-44	5.5	68
34	Future options with capecitabine (Xeloda) in (neo)adjuvant treatment of breast cancer. <i>Seminars in Oncology</i> , <b>2004</b> , 31, 45-50	5.5	56
33	Patient management issues in metastatic bone disease. <i>Seminars in Oncology</i> , <b>2004</b> , 31, 79-82	5.5	10
32	Breast cancer patients' experiences on endocrine therapy: monitoring with a checklist for patients on endocrine therapy (C-PET). <i>Breast</i> , <b>2004</b> , 13, 363-8	3.6	17
31	Tamoxifen treatment failure in cancer and the nonlinear dynamics of TGFbeta. <i>Journal of Theoretical Biology</i> , <b>2004</b> , 229, 101-11	2.3	21
30	Paclitaxel in early breast cancer: a viewpoint by David A. Cameron. <i>Drugs</i> , <b>2004</b> , 64, 1848-9	12.1	
29	Time for a change in breast cancer therapy?. <i>British Journal of Hospital Medicine</i> , <b>2004</b> , 65, 724-9		
28	Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. <i>Annals of Oncology</i> , <b>2003</b> , 14, 1391-8	10.3	188
27	Role of bisphosphonate therapy in breast cancer and other advanced malignancies. <i>Breast</i> , <b>2003</b> , 12 Suppl 2, S20-1	3.6	1
26	Proven efficacy of zoledronic acid in the treatment of bone metastases in patients with breast cancer and other malignancies. <i>Breast</i> , <b>2003</b> , 12 Suppl 2, S22-9	3.6	12
25	Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. <i>British Journal of Cancer</i> , <b>2003</b> , 89, 1837-42	8.7	100
24	Breast Cancer Therapy Annual [today] drug treatment of cancer?. <i>Breast Cancer Research</i> , <b>2003</b> , 6, 1	8.3	78
23	Breast cancer vaccines: current research and future prospects. <i>Expert Review of Vaccines</i> , <b>2002</b> , 1, 29-34	5.2	1
22	Block sequential adriamycin CMF--optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer?. <i>British Journal of Cancer</i> , <b>2002</b> , 87, 1365-9	8.7	5

21	Postcode prescribing is alive and well in Scotland. <i>BMJ, The</i> , <b>2002</b> , 325, 101A	5.9	4
20	Letrozole as primary medical therapy for locally advanced and large operable breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2001</b> , 66, 191-9	4.4	75
19	Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study. <i>British Journal of Cancer</i> , <b>2001</b> , 84, 1146-9	8.7	129
18	Brachial plexopathy affecting the development of BeauQ lines unilaterally. <i>Lancet Oncology, The</i> , <b>2001</b> , 2, 342	21.7	1
17	Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , <b>2001</b> , 79, 103-7	5.1	49
16	Aromatase inhibitors and arthralgia. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 2767	2.2	75
15	Modelling the Effects of Paclitaxel and Cisplatin on Breast and Ovarian Cancer. <i>Journal of Theoretical Medicine</i> , <b>2000</b> , 3, 11-23		2
14	Reduced MLH1 expression in breast tumors after primary chemotherapy predicts disease-free survival. <i>Journal of Clinical Oncology</i> , <b>2000</b> , 18, 87-93	2.2	87
13	Identification of long-term survivors in primary breast cancer by dynamic modelling of tumour response. <i>British Journal of Cancer</i> , <b>2000</b> , 83, 98-103	8.7	11
12	Lessons from the use of aromatase inhibitors in the neoadjuvant setting. <i>Endocrine-Related Cancer</i> , <b>1999</b> , 6, 227-30	5.7	44
11	Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1999</b> , 44, 453-60	3.5	69
10	Locally advanced breast cancer: the outcome of primary polychemotherapy based on infusional 5 fluorouracil. <i>Breast</i> , <b>1999</b> , 8, 110-5	3.6	9
9	Primary systemic therapy for operable breast cancer--10-year survival data after chemotherapy and hormone therapy. <i>British Journal of Cancer</i> , <b>1997</b> , 76, 1099-105	8.7	60
8	The expression of Ki-S1 and BCL-2 and the response to primary tamoxifen therapy in elderly patients with breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>1997</b> , 44, 123-33	4.4	49
7	Tamoxifen induced apoptosis in ZR-75 breast cancer xenografts antedates tumour regression. <i>Breast Cancer Research and Treatment</i> , <b>1997</b> , 45, 99-107	4.4	41
6	A pilot study of infusional CMF (CMF-inf): active and well tolerated in breast cancer. The Edinburgh Breast Group. <i>Annals of Oncology</i> , <b>1996</b> , 7, 409-11	10.3	2
5	Mathematical modelling of tumour response in primary breast cancer. <i>British Journal of Cancer</i> , <b>1996</b> , 73, 1409-16	8.7	9
4	Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer. <i>British Journal of Cancer</i> , <b>1996</b> , 74, 2008-12	8.7	24

- 3 High-dose chemotherapy supported by peripheral blood progenitor cells in poor prognosis metastatic breast cancer--phase I/II study. Edinburgh Breast Group. *British Journal of Cancer*, **1996**, 74, 2013-7 8.7 7
- 2 Continuous 5-fluorouracil in the treatment of breast cancer. *British Journal of Cancer*, **1994**, 70, 120-4 8.7 71
- 1 Infusional 5-fluorouracil in breast cancer. *Cancer Treatment Reviews*, **1994**, 20, 357-64 14.4 15